The global Active Pharmaceutical Ingredients CDMO market size is expected to be worth around US$ 236.1 billion by 2030, according to a new report by Vision Research Reports.
The global Active Pharmaceutical Ingredients CDMO market size was valued at US$ 91.6 billion in 2020 and is anticipated to grow at a CAGR of 12.7% during forecast period 2021 to 2030.
The growth of small molecules, rising (API) complexity, and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.
However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs, and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs.
The traditional active pharmaceutical ingredient segment dominated the market and accounted for the largest revenue share of 50.5% in 2020. The highly potent APIs segment accounted for the significant largest revenue share of 39.5% in 2020. The growth is primarily driven by rising demand for targeted cancer and other treatments. Manufacturing and technology advancements, as well as manufacturer investments, are also contributing to the growth. The majority of HPAPIs are used in the development of anti-cancer medications. Most of HPAPIs are currently tiny molecules. However, more potent compounds are emerging at a faster rate.
The antibody-drug conjugate segment is anticipated to register a lucrative growth rate of 22.3% over the forecast period. The efficacy of Antibody Drug Conjugates (ADC) and checkpoint inhibitors in the fight against cancer is having a significant impact on ADC R&D.
The biotech segment is projected to register the fastest growth rate of 10.9% over the forecast period. Factors such as rising demand for biopharmaceuticals and higher molecular efficiency are propelling segment growth. Furthermore, large investments in the biotechnology and biopharmaceutical industries might be ascribed to the rise in the segment.
The innovative drugs segment dominated the market for active pharmaceutical ingredients CDMO and accounted for the largest revenue share of 84.6% in 2020. Increased FDA approvals for new molecular entities, the high cost of innovative active pharmaceutical ingredients relative to generic pharmaceuticals, and the increased focus on R&D are all contributing to segment growth. Many unique molecules are present in the pipeline as a result of extensive research in this subject and are projected to be launched during the forecast period.
The generics drugs segment is anticipated to witness the fastest CAGR of 10.5% during the forecast period. This is largely due to patent expiration and cost-effectiveness. The generic sector is growing as a result of the growing number of patents that are scheduled to expire.
The oncology segment dominated the market for active pharmaceutical ingredients CDMO and accounted for the largest revenue share of 45.1% in 2020. Cancer therapies are driving a significant share of biologics industry growth, as well as the Highly Potent API (HPAPI) sub-sector.
The glaucoma segment accounted for the largest revenue share of 11.0% in the market for active pharmaceutical ingredients CDMO in 2020. The segment is also projected to witness the fastest CAGR of 10.0% during the forecast period. This is largely attributed due to the rising prevalence of diabetes, the growing elderly population, and the increase in healthcare spending. Brinzolamide Ophthalmic Suspension, Nyxol (Phentolamine Mesylate), and Ripasudil hydrochloride hydrate are among the prospective drugs in the Glaucoma pipeline. Some of these drugs have reached the end of their late clinical development stages, while others are still in the process.
Based on workflow, the commercial segment led the market for active pharmaceutical ingredients CDMO and accounted for the largest revenue share of 98.0% in 2020. The growth is largely attributed to the high revenue generation from the commercial active pharmaceutical ingredient production that accounts for 73.0% of commercial CDMO revenues, which is APIs' larger market share a portion of the drug's cost-of-goods in comparison to the drug's product process of production.
The clinical segment is anticipated to witness the fastest CAGR of 9.1% in the market for active pharmaceutical ingredients CDMO during the forecast period. This is largely attributed due to a record number of molecules in the preclinical and clinical development pipelines of all sorts, as well as increased R&D spending. The late phase of clinical research has the most significant impact on the value generated by the CDMO pharmaceutical industry relationship.
Asia Pacific dominated the active pharmaceutical ingredients CDMO market and accounted for the largest revenue share of 56.4% in 2020. The segment is anticipated to register the fastest CAGR of 10.9% throughout the forecast period. The significantly cheaper manufacturing costs as compared to North America and Europe and favorable laws in the region particularly China and India are factors dominating the market for active pharmaceutical ingredients CDMO in the region. While China and India have established themselves as important providers of active pharmaceutical ingredient manufacturing services, the U.S. continues to be the principal outsourcing hub for pharmaceutical development. This is due to a combination of enormous amounts of financing and a unique concentration of university-affiliated pharmaceutical research hubs. The increased importance of conventional medications and the rapidly increasing occurrence of persistent infections are important factors for the Indian API market to grow favorably.
|Market Size||US$ 236.1 billion by 2030|
|Growth Rate||CAGR of 12.7% From 2021 to 2030|
|Historic Data||2017 to 2020|
|Forecast Period||2021 to 2030|
|Segments Covered||Product, Synthesis, Drug, Application, Workflow|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)|
|Companies Mentioned||Cambrex; Recipharm; Thermo Fisher Pantheon; Corden Pharma; Samsung Biologics; Lonza; Catalent; Siegfried; Piramal Pharma Solutions; Boehringer Ingelheim|
Thermo Fisher Pantheon
Piramal Pharma Solutions
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Antibody Drug Conjugate (ADC)
Middle East & Africa
The Active Pharmaceutical Ingredients CDMO market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Active Pharmaceutical Ingredients CDMO market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Active Pharmaceutical Ingredients CDMO market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Active Pharmaceutical Ingredients CDMO market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Active Pharmaceutical Ingredients CDMO market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Active Pharmaceutical Ingredients CDMO capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Active Pharmaceutical Ingredients CDMO by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Active Pharmaceutical Ingredients CDMO market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Active Pharmaceutical Ingredients CDMO market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Active Pharmaceutical Ingredients CDMO market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Active Pharmaceutical Ingredients CDMO industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Active Pharmaceutical Ingredients CDMO market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Active Pharmaceutical Ingredients CDMO market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Active Pharmaceutical Ingredients CDMO market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Active Pharmaceutical Ingredients CDMO market. These factors have benefited the growth of the global market for Active Pharmaceutical Ingredients CDMO. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Active Pharmaceutical Ingredients CDMO. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Active Pharmaceutical Ingredients CDMO are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Omics-based Clinical Trials Market (By Product: Phase I, Phase II, Phase III, Phase IV; By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies; By Indication : Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases (includes the rare diseases), Others (includes ophthalmic, ear diseases, etc)) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Complementary and Alternative Medicine for Anti Aging & Longevity Market (By Intervention : Traditional Alternative Medicine/Botanicals, Body Healing, Mind Healing, External Energy Healing, Sensory Healing; By Customer: High Net Worth (HNW) Individuals, Very High Net Worth (VHNW) Individuals, Ultra-high Net Worth (UHNW) Individuals) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Defibrillator Market (By Product: Implantable Cardioverter Defibrillators (ICD), External Defibrillators (ED); By End-use: Hospital, Pre Hospital, Public Access Market, Alternate Care Market, Home Healthcare) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Medical Fiber Optics Market (By Fiber Type: Single Mode Optical Fiber, Multimode Optical Fiber; By Application: Endoscopic Imaging, Laser Signal Delivery, Biomedical Sensing, Illumination) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Pharmacovigilance Market (By Service Provider: In-house, Contract Outsourcing; By Product Life Cycle: Pre-clinical, Phase I, Phase II, Phase III, Phase IV; By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining; By Process Flow: Case Data Management, Signal Detection, Risk Management System) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...